You experience chest pain, shortness of breath, or swelling in your legs or ankles , which may indicate worsening heart failure or another cardiovascular issue requiring urgent evaluation
Semaglutide (Wegovy, Ozempic), Tirzepatide (Mounjaro), and Liraglutide (Saxenda), based on clinical appropriateness and pharmacy availability
GLP-1R agonists have reducing neuroinflammation and oxidative stress, neurotrophic effects, decreasing A deposition and tau hyperphosphorylation in AD models, which may be a potential drug for the treatment of AD
Common Side Effects These side effects are more frequently reported: Gastrointestinal Issues: Nausea, vomiting, diarrhea, constipation, and abdominal pain are common with Wegovy
Interleukin inhibitors : Ustekinumab (Stelara) targets IL-12 and IL-23 pathways, while risankizumab (Skyrizi) specifically inhibits IL-23
Semaglutide was added to the FDA drug shortage database in 2022